ChIP Sequencing Kit for Next Generation Sequencing
Porvair Sciences has developed a new ChIP sequencing assay kit extending the benefits of their proprietary Chromatrap solid state ChIP technology to preparation of purified Chromatin for the generation of sequencing libraries.
Chromatin immunoprecipitation (ChIP) is a technique used to detect interactions between proteins and DNA, and is based on the enrichment of DNA associated with a specific protein of interest. Combining ChIP with massively parallel sequencing (ChIP-seq) allows the accurate survey of interactions between proteins and DNA, enabling the study of epigenetic marks, which is essential for a full understanding of transcriptional regulation of genes. A precise and detailed map of protein interactions with DNA is vital for interpreting regulatory networks that underlie many biological processes and disease states, including cancer. Recent advances have identified that that the interplay between chromatin and transcription is much more dynamic and complex than initially anticipated. Previous technology using microarrays were limited by the number of unique species-specific oligonucleotide probes that could be hybridised to the chip surface. Next generation sequencing has the ability to sequence tens or hundreds of millions of short DNA fragments simultaneously, without being hybridised to an array. With single-base pair resolution, fewer artefacts, greater coverage and a larger dynamic range, ChIP-seq offers significant advantages over past technology and experiments which could only be imagined a few years ago are now becoming a reality.
Chromatrap is a new quicker, easier and more efficient way of performing ChIP-seq assays (Patent No. GB2482209). It uses discs of an inert, porous polymer to which Protein A or Protein G has been covalently attached to maximise the capture efficiency of the target chromatin/antibody complex. Chromatrap utilises the solid state technology in parallel with high throughput sequencing to deliver a precise ChIP-seq protocol from small cell numbers and chromatin concentrations. Specifically adapted for greater chromatin concentrations, Chromatrap ChIP-seq now combines the dynamic range of Chromatrap with the downstream analysis power of deep sequencing, allowing the genome wide identification of transcription factor binding sites and specific DNA associated protein modifications with no limitation in scale and resolution.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance